Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ROBO1
REST API REST API
Homo sapiens
ROBO1 is differentially expressed in 268 experiments: 106 organism parts: brain, bone marrow, ... (104 more);, 175 disease states: normal, prostate carcinoma, ... (173 more);, 72 cell types 511 cell lines 23 compound treatments and 57 other conditions.
Synonyms SAX3, FLJ21882, DUTT1
Orthologs ROBO1 (Bos taurus)   Robo1 (Rattus norvegicus)   ROBO1 (Gallus gallus)   robo1 (Danio rerio)   Robo1 (Mus musculus)   robo (Drosophila melanogaster)   robo3 (Drosophila melanogaster)   lea (Drosophila melanogaster)   robo1 (Xenopus laevis)   XM_544814.2 (Canis familiaris)   ENSCAFG00000024476 (Canis familiaris)   (Compare orthologs)
InterPro Term Ig_V-set, Ig_sub, Immunoglobulin, Ig-like, Ig_sub2, Ig_I-set, Ig_V-set_subgr, Fibronectin_type3
Gene Ontology Term plasma membrane, axon midline choice point recognition, protein binding, axon, cytoplasm, negative regulation of cell proliferation, homophilic cell adhesion, activation of caspase activity, axon guidance receptor activity, cell differentiation, identical protein binding, cell adhesion, axon guidance, multicellular organismal development, integral to plasma membrane, protein heterodimerization activity, receptor activity, nervous system development, cell surface, regulation of dendrite morphogenesis, central nervous system development, neuronal cell body, positive regulation of axonogenesis, LRR domain binding, Roundabout signaling pathway, spinal cord development, cell migration involved in sprouting angiogenesis, axolemma, chemorepulsion involved in postnatal olfactory bulb interneuron migration, mammary duct terminal end bud growth, negative regulation of negative chemotaxis, olfactory bulb interneuron development, negative regulation of chemokine-mediated signaling pathway, negative regulation of mammary gland epithelial cell proliferation
UniProt Accession Q9Y6N7, Q2M1J3, B2RXI1, C9JVN5, E9PD49, F8WEV8, F8WAA2
Search EB-eye ENSG00000169855
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (46 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
SW480
3
E-MEXP-1014, E-GEOD-2509, E-MTAB-37
A549
2
E-GEOD-6013, E-GEOD-3202
AGS
2
E-MTAB-37, E-GEOD-15460
BT474
2
E-MEXP-440, E-MTAB-62
DU145
2
E-GEOD-17482, E-GEOD-20089
505 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-19397, E-MEXP-66, E-GEOD-4219, E-GEOD-20677, ... (39 experiments)

Factor Value U/D Experiments
CD4+ T cell
1
3
E-MEXP-1600, E-GEOD-6740, E-GEOD-19069, E-AFMX-5
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
epidermoid
1
E-GEOD-19397
epithelial cells
1
E-GEOD-20758
erythropoietic
1
E-GEOD-9894
66 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-1121, ... (49 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-6014, E-MTAB-62, E-MTAB-37
prostate carcinoma
1
3
E-TABM-26, E-MEXP-1327, E-GEOD-96, E-MEXP-2034
T-cell acute lymphoblastic leukemia
2
E-MTAB-37, E-GEOD-1577
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
colon carcinoma
2
E-MTAB-62, E-MTAB-37
gastric carcinoma
2
E-MTAB-37, E-GEOD-15460
169 more value(s).


Compound treatment

studied in E-GEOD-15205, E-GEOD-1417, E-TABM-868, E-GEOD-15811, E-GEOD-5099, ... (14 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
control - untreated
1
E-GEOD-7216
Cxcl12
1
E-GEOD-7307
M-CSF
1
E-GEOD-5099
17beta-estradiol
4
1
E-GEOD-4006
TGF
1
E-GEOD-15205
17 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-MTAB-37, E-TABM-176, E-GEOD-19348, E-MEXP-1251, E-GEOD-1563, ... (10 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (9 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-GEOD-21138, E-GEOD-19665

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-763, E-GEOD-1045, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-2657, E-GEOD-12773, E-TABM-127, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (33 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-17400

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-1460

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-MEXP-114, E-GEOD-1147, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307 ... (5 experiments)

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

Processing time: 0.26 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM